U.S. Markets closed

Calliditas Therapeutics AB (publ) (CALT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
22.85-0.14 (-0.59%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close22.98
Bid22.00 x 800
Ask29.00 x 800
Day's Range22.73 - 23.30
52 Week Range20.50 - 38.00
Avg. Volume32,206
Market Cap570.458M
Beta (5Y Monthly)1.51
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est51.60
  • PR Newswire

    Updated regulatory timeline for review of MAA in Europe

    Calliditas Therapeutics AB (publ) ("Calliditas" or the "Company") (Nasdaq Stockholm: CALTX) (Nasdaq: CALT), a biopharma company focused on identifying, developing and commercializing novel treatments in orphan indications, today announced that the European Medicine Agency's (EMA) Committee for Human Medicinal Products (CHMP)) has decided to continue the assessment of the marketing authorization application (MAA) for Nefecon under standard procedure assessment timelines.

  • Benzinga

    The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14) Alcon Inc. (NYSE: ALC) aTyr Pharma, Inc. (NASDAQ: LIFE) (reacted to positive analyst action following a positive clinical readout announced Monday) Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) BELLUS Health Inc. (NASDAQ: BLU) Itamar Medical Ltd. (NASDAQ: ITMR) IVERIC bio, Inc. (NASDAQ: ISEE) Kezar Life Sciences, Inc. (NASDAQ: KZR) PPD, Inc. (NASDAQ: P

  • Benzinga

    Calliditas Therapeutics Stock Falls As FDA Pushes Nefecon PDUFA Goal Date To December

    The FDA has extended the PDUFA goal date for Calliditas Therapeutics AB's (NASDAQ: CALT) application seeking accelerated approval for Nefecon. Nefecon is an oral formulation targeting down-regulation of IgA1 to treat primary IgA Nephropathy (IgAN). The new goal date is December 15 compared to the previous September 15. The FDA has requested further analyses of the NeflgArd trial data, which the company has provided to the FDA. The amendment mainly provides additional eGFR and other related analy